Pfizer, Moderna, and Johnson & Johnson said at the Group of Twenty (G20) Health Summit on Friday (May 21) that they will provide low- and middle-income countries at a cost or discounted price this year and next year. Approximately 3.5 billion doses of vaccine are provided.
Pfizer President Albert Bourla said that Pfizer will provide 2 billion doses of vaccine “in the next 18 months.” Pfizer and BioNTech will supply vaccines to low- and middle-income countries through the Global Coronary Disease Vaccine Access System (COVAX). A Pfizer spokesperson stated that the vaccine will be distributed “through bilateral agreements, agreements with supranational organizations, and our partnership with COVAX.”
Moderna President Stephane Bancel said that Modena will provide “up to 95 million doses of vaccine this year, and “up to 900 million doses of vaccine” next year, including through COVAX.
Johnson & Johnson vice chairman and chief scientific officer Paul Stoffels (Paul Stoffels) said that the company has reached an agreement with COVAX to provide up to 200 million doses of vaccine this year, and is discussing the possibility of providing an additional 300 million doses, totaling 500 million doses.